Removal of intact Delta b2-microglobulin at neutral ph by using seed-conjugated polymer beads prepared with Delta b2-microglobulin-derived peptide (58-67)
Removal of Delta *b2-microglobulin ( Delta *b2M) from the blood of patients suffering from kidney dysfunction is crucial to protect those individuals from getting the diseased state of dialysis-related amyloidosis. By harnessing the nucleation-dependent fibrillation process of amyloidogenesis, a Del...
Gespeichert in:
Veröffentlicht in: | Biotechnology progress 2011-03, Vol.27 (2), p.521-529 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Removal of Delta *b2-microglobulin ( Delta *b2M) from the blood of patients suffering from kidney dysfunction is crucial to protect those individuals from getting the diseased state of dialysis-related amyloidosis. By harnessing the nucleation-dependent fibrillation process of amyloidogenesis, a Delta *b2M removal strategy has been proposed by preparing seed-conjugated polymer beads and assimilating soluble Delta *b2M to the fibrils on the surface at neutral pH. A novel peptide segment of Delta *b2M ranging from residue 58 to residue 67 (Lys-Asp-Trp-Ser-Phe-Tyr-Leu-Leu-Tyr-Tyr), which was capable of being fibrillated at neutral pH was isolated. Charge interaction between the positive N-terminal lysine and the negative C-terminal -carboxylic group was demonstrated to be critical for the molecular self-assembly leading to the peptide fibril formation by favoring Delta *b-sheet conformation. Because the peptide fibrils were successful to seed intact Delta *b2M at neutral pH, the fibrils were immobilized on polymer beads of HiCore resins, and the resulting seed-conjugated beads were used to accrete intact Delta *b2M in the form of fibrils elongated on the bead surface. Its efficiency of the Delta *b2M removal was improved by placing the seed-immobilized beads in the middle of a continuous flow of the Delta *b2M-containing solution as practiced in the blood circulation during the hemodialysis. Therefore, this Delta *b2M removal system is suggested to exhibit high specificity, high binding capacity, and cost-effectiveness appropriate for eventual clinical application to remove Delta *b2M from the blood of renal failure patients. [copy 2011 American Institute of Chemical Engineers Biotechnol. Prog., 2011 |
---|---|
ISSN: | 1520-6033 |
DOI: | 10.1002/btpr.562 |